Drug
Xelox clinical trials
- studies test it
- 50
- open now
- 22
- in phase 3
- 10
- first study started
- 2003
Keep track of what changes. Save the xelox studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Combined with it in one product
Studies by the year they started
50 studies that test it; most in 2023 (6)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2006 | 3 |
| 2010 | 2 |
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 2 |
| 2014 | 1 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 5 |
| 2019 | 2 |
| 2020 | 5 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 6 |
| 2024 | 3 |
| 2025 | 6 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 37
- Phase 3
- 10
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 45
Harbin Medical University (4) · Peking University Cancer Hospital & Institute (2) · AstraZeneca (2) · Fudan University (2) · The First Affiliated Hospital with Nanjing Medical University (2) · fan li (2) · Daping Hospital and the Research Institute of Surgery of the Third Military Medical University (2) · China Medical University, China (2)
Often tested with
Tested in the same studies.
CAPOX Regimen (15) · Bevacizumab (6) · Folfox protocol (4) · Capecitabine (4) · XELIRI Regimen (4) · Modified FOLFOX Regimen (3) · Oxaliplatin (3) · FOLFOXIRI Regimen (3)
Studies
Open first, then newest update. How each study uses xelox is read from its arms, and is right about nine times in ten.
Testing it · 50
- Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal CancerRecruitingPhase 2Sun Yat-sen UniversityNCT07448142Written as CAPEOX/XELOX
- A Single-arm, Multicenter Clinical Study of Fruquintinib Combined With Serplulimab and Chemotherapy as First-line Treatment for Patients With RAS/BRAF-mutated Advanced Colorectal CanceNot yet recruitingPhase 2Jiangsu Cancer Institute & HospitalNCT07622550Written as Serplulimab+Fruquintinib+XELOX
- Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaRecruitingPhase 2AstraZenecaNCT05702229Written as XELOX
- LDRT Combined With Immunochemotherapy for Colorectal Cancer With Liver MetastasisRecruitingPhase 1Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityNCT06848465Written as XELOX
- Umbrella Trial of Neoadjuvant Therapy for Locally Advanced Colorectal CancerNot yet recruitingPhase 2Fudan UniversityNCT07503639Written as XELOX (Capecitabine and Oxaliplatin)
- SCRT-CAPEOX-Serplulimab for MSS/pMMR Rectal Cancer With OligometastasesRecruitingPhase 2First Affiliated Hospital of Zhejiang UniversityNCT06850103Written as CAPEOX/XELOX
- A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E MutationNot yet recruitingPhase 2Yanqiao ZhangNCT07229846Written as XELOX + Bevacizumab
- QL1706 Plus XELOX as Neoadjuvant Therapy for MSS/pMMR Clinical Stage III Colon CancerNot yet recruitingPhase 2Qilu Hospital of Shandong UniversityNCT07156682Written as XELOX
- SCRT Sequential Penpulimab in Combination With CAPEOX in the Neoadjuvant Treatment of MSS Locally Advanced Rectal CancerRecruitingPhase 2Ruijin HospitalNCT05576480Written as CAPEOX
- Iparomlimab/Tuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy for Colorectal Cancer Liver MetastasisNot yet recruitingPhase 2Peking University Cancer Hospital & InstituteNCT07007728Written as Bevacizumab + CAPEOX
- Neoadjuvant Short-Course Radiotherapy With or Without Chemotherapy and AK112 in Locally Advanced Rectal CancerRecruitingPhase 2fan liNCT06718543Written as AK112 with SCRT and CapeOX
- SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer.Not yet recruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT06835179Written as CapeOX + bevacizumab
- HDAC Inhibitor Combination with Chemoimmunotherapy in the Neoadjuvant Treatment of PMMR Locally Advanced Colon CancerRecruitingPhase 2Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityNCT06709885Written as Chidamide + Tislelizumab + chemotherapy (CapeOX )
- A Phase II Trial of Perioperative Adebrelimab Combined With XELOX in Resectable Locally Advanced Gastric/Gastroesophageal Junction Cancer (GC/GEJC)RecruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT06506292Written as XELOX
- AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ CancerRecruitingPhase 2Harbin Medical UniversityNCT06196697Written as XELOX
- Phase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GCRecruitingPhase 2Peking UniversityNCT06023758Written as XELOX
- Modified Sandwich Therapeutic Regimen for Locally Advanced Rectal CancerRecruitingPhase 2Zhen-Hai LuNCT05228431Written as XELOX
- Treatment of Low Locally Advanced Rectal Cancer With Radiotherapy Removal TNT Plus Neoadjuvant TherapyNot yet recruitingNot applicableTang-Du HospitalNCT06035133Written as CapeOX + cetuximab
- Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal CancerRecruitingPhase 2Federation Francophone de Cancerologie DigestiveNCT04659382Written as XELOX
- Neoadjuvant Arterial Embolization Chemotherapy Combined PD-1 Inhibitor for Locally Advanced Rectal CancerRecruitingPhase 2The Fourth Affiliated Hospital of Zhejiang University School of MedicineNCT05420584Written as XELOX
See all 50 studies that test xelox →
Given in every arm · 24 — xelox is usual care beside what is tested
- Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric CancerRecruitingNot applicableTang-Du HospitalNCT06128252Written as XELOX regimen
- A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon CancerRecruitingPhase 2GlaxoSmithKlineNCT06567782Written as CAPEOX
- XELOX Plus DoSTARlimab Versus XELOX Alone as Consolidation Treatment After Standard Chemoradiation in pMMR/MSS or MSI-Low Locally Advanced Rectal Cancer (LARC) PatientsNot yet recruitingPhase 2Gruppo Oncologico Italiano di Ricerca ClinicaNCT07381777Written as XELOX (Capecitabine and Oxaliplatin)
- Adebrelimab Combined With Induction Chemotherapy or SHR-8068 for Mismatch Repair-Deficient/Microsatellite Instability-High (dMMR/MSI-H) Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma：A Randomized, Non-comparative Phase 2 StudyNot yet recruitingPhase 2Shanghai Zhongshan HospitalNCT07266025Written as XELOX
- Phase II Clinical Study of AC591 in Preventing Oxaliplatin-Induced Peripheral NeuropathyNot yet recruitingPhase 2Shandong New Time Pharmaceutical Co., LTDNCT06722950Written as CAPEOX
- Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ PatientsRecruitingPhase 1/2Zhejiang Cancer HospitalNCT06650332Written as XELOX
- Clinical Study of Taurine Combined With Sintilimab and Chemotherapy for Treatment of Advanced Gastric CancerRecruitingPhase 2Tang-Du HospitalNCT06123455Written as XELOX regimen
- XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction AdenocarcinomaRecruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT05494060Written as XELOX
- KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary CarcinomaNot yet recruitingPhase 2Peking University Cancer Hospital & InstituteNCT05985707Written as XELOX
- The Value of Palliative Primary Tumor Resection in Metastatic Colon CancerRecruitingPhase 3Fudan UniversityNCT04416854Written as XELOX
- Prospectively Randomized Control Clinical Trial of FOLFOXIRI Preoperative Chemotherapy Alone on Rectal Cancer in Local Advance Comparing to Oral Capecitabine Combined With Long-term RadiationRecruitingPhase 3Sun Yat-sen UniversityNCT03671252Written as XELOX
- XELOX Plus Apatinib vs XELOX as Post-operative Chemotherapy in Locally Advanced Gastric Signet Ring CarcinomaNot yet recruitingPhase 3Tianjin Medical University Cancer Institute and HospitalNCT03355612Written as XELOX
- Adaptive Boost Radiotherapy to Primary Lesions and Positive Nodes in the Neoadjuvant Treatment of Locally Advanced Rectal CancerActive, not recruitingPhase 3Shandong Cancer Hospital and InstituteNCT06246344Written as CAPEOX
- Clinical Study of Regorafenib and Nivolumab Plus ChemotherapyCompletedPhase 1/2National Cancer Center Hospital EastNCT05394740Written as CapeOX
- Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal TumorsCompletedPhase 2Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityNCT05515796Written as CapeOx
- Organ Preservation Program Using Short-Course Radiation & FOLFOXIRI in Rectal CancerCompletedPhase 2Stanford UniversityNCT04380337Written as XELOX
- An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) CancersCompletedPhase 2Bristol-Myers SquibbNCT03662659Written as XELOX
- SCRT Followed by Camrelizumab Combined With Fluzoparib and Chemotherapy as Neoadjuvant Therapy for LARCStatus unknownPhase 2Huazhong University of Science and TechnologyNCT06516445Written as CAPEOX
- Multi-Line Therapy Trial in Unresectable Metastatic Colorectal CancerActive, not recruitingPhase 3GERCOR - Multidisciplinary Oncology Cooperative GroupNCT01910610Written as XELOX + bevacizumab
- Camrelizumab Combined With Trastuzumab and Chemotherapy in Patients With HER2-positive Advanced Colorectal CancerStatus unknownPhase 2Fudan UniversityNCT05193292Written as XELOX regimen
Showing 20 of 24.
As the comparator · 13 — what is tested is compared with xelox
- Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric AdenocarcinomasRecruitingPhase 3Centre Leon BerardNCT06346197Written as XELOX
- Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon CancerRecruitingPhase 3GlaxoSmithKlineNCT05855200Written as CAPEOX
- A Study of Neoadjuvant QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon CancerRecruitingPhase 3Qilu Pharmaceutical Co., Ltd.NCT06686576Written as CAPEOX/Capecitabine
- CtDNA in Adjuvant Chemotherapy of Stage III Colon Cancer (REVISE Trial)RecruitingPhase 2West China HospitalNCT06242418Written as XELOX
- Neoadjuvant Fruquintinib Plus Tislelizumab Combined With mCapeOX Versus CapeOX for Mid-high pMMR/MSS Locally Advanced Rectal CancerNot yet recruitingPhase 2/3Peking University Cancer Hospital & InstituteNCT06443671Written as CapeOX
- Envafolimab Monotherapy or Envafolimab + CAPEOX as Neoadjuvant Therapy for Locally Advanced Colorectal CancerRecruitingPhase 2Sun Yat-sen UniversityNCT06014372Written as CAPEOX
- Perioperative FLOT vs Adjuvant XELOX for CA StomachRecruitingPhase 3Chinese University of Hong KongNCT05264896Written as XELOX
- PD-1 Antibody Adjuvant Therapy for GC Patients With MSI-H After D2 Radical SurgeryActive, not recruitingPhase 2Fudan UniversityNCT05468138Written as XELOX
- Assessment of Ramucirumab Plus Paclitaxel as Switch MANteInance Versus Continuation of First-line Chemotherapy in Patients With Advanced HER-2 Negative Gastric or Gastroesophageal Junction CancersStatus unknownPhase 3Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoNCT02934464Written as XELOX
- A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, MK-7454-003)CompletedPhase 2Merck Sharp & Dohme LLCNCT00551213Written as CAPEOX/XELOX
- SOX Versus XELOX for Patients With Peritoneal Metastasis of Colorectal CancerStatus unknownPhase 2The First People's Hospital of ChangzhouNCT02870153Written as XELOX
- Trial of Adjuvant Chemotherapy for High Risk Gastric Cancer PatientsStatus unknownPhase 2Tianjin Medical University Cancer Institute and HospitalNCT01618474Written as XELOX
- Oxaliplatin and S-1 (OS) Versus Oxaliplatin and Capecitabine (XELOX) for Advanced Colorectal CancerCompletedPhase 2Hallym University Medical CenterNCT00677144Written as XELOX (oxalipaltin+capecitabine)